A. Alegre et al., BUSULFAN AND MELPHALAN AS CONDITIONING REGIMEN FOR AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION IN MULTIPLE-MYELOMA, British Journal of Haematology, 91(2), 1995, pp. 380-386
Twenty-four patients with multiple myeloma (MM), three (12.5%) in comp
lete remission (CR) and 21 (87.5%) in partial remission (PR) were trea
ted with high-dose chemotherapy (HDCT) (busulfan 12 mg/kg + melphalan
140mg/m(2)) as preparative regimen for autologous peripheral blood ste
m cell (PBSC) transplantation. These cells were previously collected b
y leukapheresis after mobilization by high-dose cyclophosphamide (HD C
y) + rhGM-CSF (18 patients) or rhG-CSF alone (six patients). Consideri
ng 23 evaluable patients following HDCT, the CR rate was 58% (14 patie
nts) and the PR rate was 38% (nine patients). One transplant-related d
eath occurred following this regimen (4%). With a median follow-up of
20 months (range 4-34) after transplantation, 21 patients are alive (8
7%). Disease progression after transplantation was observed in four pa
tients. Overall and relapse-free actuarial survival at 24 months was 9
1% and 74%, respectively. 12 patients (50%) remain in CR 15 months (4-
34) post transplant. The major toxicity was mucositis. Busulfan + melp
halan is a safe and feasible conditioning regimen for APBSCT in MM wit
h acceptable toxicity and a high objective response rate, which may re
sult in prolonged survival.